Skip to content

Effect of aspiration thrombectomy combined with tirofiban on microvascular obstruction in STEMI patients: a prospective, randomised controlled cardiac magnetic resonance trail

Effect of aspiration thrombectomy combined with tirofiban on microvascular obstruction in STEMI patients: a prospective, randomised controlled cardiac magnetic resonance trail

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500103163
Enrollment
Unknown
Registered
2025-05-26
Start date
2025-06-01
Completion date
Unknown
Last updated
2025-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ST-segment elevation myocardial infarction

Interventions

Aspiration thrombectomy group:Aspiration thrombectomy
No aspiration thrombectomy group:None

Sponsors

Changzhou Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.The patient presented with symptoms of myocardial ischaemia lasting >=30 min; definite ECG changes suggestive of STEMI: ST-segment elevation of >0.1 mV in adjacent limb leads or >=0.2 mV in adjacent thoracic leads; 2.Received direct PCI treatment: within 12 hours of onset, or 12-24 hours of onset but still with persistent symptoms, haemodynamic instability or fatal arrhythmia; 3.Aged between 18 years and 80 years. 4.High thrombus load: 1). TIMI thrombus grade 3 or 4 on coronary angiography. 2). TIMI thrombus >= grade 3 after guidewire passage or pre-dilatation of the offender's lesion 1.5 mm diameter if the emergency coronary angiogram shows TIMI thrombus grade 5 (TIMI flow grade 0). 5.No grossly tortuous or calcified lesions in the responsible vessel; 6. Informed consent.

Exclusion criteria

Exclusion criteria: 1.contraindications for tirofiban use; 2.prior fibrinolysis; 3.active severe bleeding; 4.history of major surgery < 4 weeks; 5.cardiogenic shock with mechanical ventilation; 6.severe hepatic and renal dysfunction; 7.the presence of previous myocardial infarction or coronary artery bypass grafting; 8.contrain- dications to magnetic resonance imaging, such as implanted pacemakers, defibrillators, or metallic intracranial implants.

Design outcomes

Primary

MeasureTime frame
MVO mass;Major adverse cardiovascular events(MACE);Infarct size(IS);

Secondary

MeasureTime frame
Intramyocardial haemorrhage(IMH);Myocardial salvage index (MSI);

Countries

China

Contacts

Public ContactXin Chen

Changzhou Second People's Hospital

13506126702@126.com+86 13506126702

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026